Literature DB >> 12592308

17. Immunologic endocrine disorders.

Devasenan Devendra1, George S Eisenbarth.   

Abstract

Immune-mediated tissue destruction or disregulation is the cause of multiple common, as well as rare, endocrine disorders including type 1 diabetes, Graves' disease, Hashimoto thyroiditis, and Addison's disease. Each of these disorders can be divided into a series of stages beginning with genetic susceptibility, environmental triggering events, and active autoimmunity, followed by metabolic abnormalities with overt disease. Common genetic susceptibility is suggested by the clustering of a series of disorders in the same individual and his or her family. A major portion of the genetic susceptibility lies in the HLA region, but for several disorders, mutation of transcription factors underlies disease susceptibility (eg, X-linked polyendocrinopathy, immune deficiency and diarrhea, and autoimmune polyendocrine syndrome type 1). With improving immunogenetic and pathogenic understanding, type 1A diabetes is now predictable, and excellent autoantibody screening assays are available. This knowledge, combined with studies in animal models, has led to trials for the prevention of diabetes. In addition, aberrant immunologic reactions (eg, insulin autoantibodies after insulin therapy, Graves' disease after monoclonal anti-T-cell therapy in multiple sclerosis) can complicate standard and experimental therapies. We therefore believe that an understanding of the immunogenetics and immunopathogenesis of endocrine disorders can aid in the prevention of morbidity and mortality for these related diseases.

Entities:  

Mesh:

Year:  2003        PMID: 12592308     DOI: 10.1067/mai.2003.81

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  11 in total

1.  Cationic nanomicelles for delivery of plasmids encoding interleukin-4 and interleukin-10 for prevention of autoimmune diabetes in mice.

Authors:  Rhishikesh Mandke; Jagdish Singh
Journal:  Pharm Res       Date:  2011-11-11       Impact factor: 4.200

Review 2.  Type 1 diabetes: recent developments.

Authors:  Devasenan Devendra; Edwin Liu; George S Eisenbarth
Journal:  BMJ       Date:  2004-03-27

Review 3.  From markers to molecular mechanisms: type 1 diabetes in the post-GWAS era.

Authors:  Alan G Baxter; Margaret A Jordan
Journal:  Rev Diabet Stud       Date:  2012-12-28

Review 4.  Type 1 diabetes: pathogenesis and prevention.

Authors:  Kathleen M Gillespie
Journal:  CMAJ       Date:  2006-07-18       Impact factor: 8.262

5.  Berson, Yalow, and the JCI: the agony and the ecstasy.

Authors:  C Ronald Kahn; Jesse Roth
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

6.  Estimation of genetic risk for Type 1 diabetes mellitus in newborns on dried blood spot.

Authors:  A Giannattasio; U Caruso; F Napoli; A Salina; C Aloi; R Lorini; G d'Annunzio
Journal:  J Endocrinol Invest       Date:  2010-01-22       Impact factor: 4.256

7.  Immunogenetics of Hashimoto's thyroiditis.

Authors:  Dimitry A Chistiakov
Journal:  J Autoimmune Dis       Date:  2005-03-11

8.  Clinical Implications of the Coexistence of Anemia and Diabetes Mellitus in the Elderly Population.

Authors:  S S Michalak; E Wolny-Rokicka; E Nowakowska; M Michalak; L Gil
Journal:  J Diabetes Res       Date:  2021-10-18       Impact factor: 4.011

9.  Defective suppressor function of human CD4+ CD25+ regulatory T cells in autoimmune polyglandular syndrome type II.

Authors:  Martin A Kriegel; Tobias Lohmann; Christoph Gabler; Norbert Blank; Joachim R Kalden; Hanns-Martin Lorenz
Journal:  J Exp Med       Date:  2004-04-26       Impact factor: 14.307

10.  A type 1 diabetes genetic risk score can discriminate monogenic autoimmunity with diabetes from early-onset clustering of polygenic autoimmunity with diabetes.

Authors:  Matthew B Johnson; Kashyap A Patel; Elisa De Franco; Jayne A L Houghton; Timothy J McDonald; Sian Ellard; Sarah E Flanagan; Andrew T Hattersley
Journal:  Diabetologia       Date:  2018-02-07       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.